← Back
Data updated: Mar 10, 2026
SIGMAPHARM LABS LLC
CardiovascularInfectious DiseaseRespiratory
SIGMAPHARM LABS LLC is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Respiratory.
2009
Since
17
Drugs
-
Trials
60
Approved (2yr)
Recent Activity
SODIUM PHENYLBUTYRATE 2026-02-17
AMBRISENTAN 2026-02-17
Labeling
AMBRISENTAN 2026-02-17
Labeling
AMBRISENTAN 2026-01-18
Labeling
AMBRISENTAN 2026-01-18
Labeling
PROTRIPTYLINE HYDROCHLORIDE 2026-01-07
Labeling
POTASSIUM CHLORIDE 2025-12-22
NITROGLYCERIN 2025-12-18
POTASSIUM CHLORIDE 2025-11-20
POTASSIUM CHLORIDE 2025-10-27
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 33%
2 drugs
Infectious Disease 33%
2 drugs
Respiratory 17%
1 drugs
Immunology 17%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Novartis big-pharma
Cardiovascular, Immunology, Respiratory
Merck big-pharma
Infectious Disease, Cardiovascular, Immunology
Johnson & Johnson big-pharma
Immunology, Infectious Disease, Cardiovascular
GSK big-pharma
Infectious Disease, Respiratory, Immunology
Sanofi big-pharma
Infectious Disease, Immunology, Respiratory
Active (11)
Discontinued (5)
Company Info
- First Approval
- 2009-01-30
- Latest
- 2026-02-17
- Applications
- 18